PHE News

Precision for Medicine Acquires Precision Health Economics

Extends Leadership in Health Economics and Outcomes Research With a Focus on Evidence Generation in an Era of Precision Medicine.

Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics (PHE).


Philipson in Forbes: Do We Want Centralized or Decentralized Medicine?

Precision founding partner Tomas Philipson's latest Op-Ed addresses the growing restrictions placed by insurance plans on innovative therapies.


Goldman & Lakdawalla in Health Affairs Blog: "Moving Beyond Pay-Per-Dose"

Precision Health Economics founding partners Dana Goldman and Darius Lakdawalla address the need to evolve beyond pay-per-dose pricing in the pharmaceutical industry.


Precision's Goldman and Lakdawalla Participate in "Future of Specialty Drugs" DC Conference

Precision Health Economics founding partners Dana Goldman and Darius Lakdawalla recently participated in a thought-leader conference focusing on the future of specialty drugs. Click below to view complete video of the event, photo gallery, complete speaker line-up and more!


Philipson Addresses Innovation in Celgene Newsroom Article

PHE founding partner Tomas Philipson is interviewed for Celgene Newsroom.

  • Academic Insights at

    the Speed of Business

  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Medicine, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

  • Academic Insights at

    the Speed of Business